|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Schizophrenia: normal sequence in the dopamine D2 receptor region that couples to G-proteins. DNA polymorphisms in D2.
|
8471125 |
1993 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dopamine receptor D2 -141C Insertion/Deletion polymorphism in a Finnish population with schizophrenia.
|
14572625 |
2003 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
|
17362435 |
2007 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
|
17362435 |
2007 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DRD2 polymorphisms correlate with neuropsychiatric disorders, in particular alcoholism and schizophrenia.
|
19929252 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dopamine D(2) receptor antagonism is a unifying property of all antipsychotic drugs in use for schizophrenia.
|
20579747 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.
|
20664489 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.
|
21187413 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
DRD2 Schizophrenia-Risk Allele Is Associated With Impaired Striatal Functioning in Unaffected Siblings of Schizophrenia Patients.
|
26598739 |
2016 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
DRD2 antagonists routinely used for management of schizophrenia might be tested in patients with pancreatic cancer.
|
27578530 |
2016 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups.
|
28094812 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A functional polymorphism in the promoter region of the dopamine D2 receptor gene (DRD2) has been reported to be associated with schizophrenia.
|
11740982 |
2001 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
A functional polymorphism in the promoter region of the DRD2 gene has been found to be associated with schizophrenia in Japanese(1,2) and Swedish populations.
|
12399954 |
2002 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A functional polymorphism in the promoter region of the DRD2 gene has been found to be associated with schizophrenia in Japanese(1,2) and Swedish populations.
|
12399954 |
2002 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes.
|
20138949 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A MEDLINE search of articles available up to December 31, 2008, yielded 18 prospective studies examining DRD2 gene variation and antipsychotic response in schizophrenia patients; of which, 10 independent studies met criteria for inclusion.
|
20194480 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A mutation in the DRD2 receptor gene has been reported in association with schizophrenia in Japanese and Caucasian populations.
|
8886166 |
1996 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A regulatory dopamine 2-receptor gene (DRD2) polymorphism (rs1076560; G>T) has been identified as a genetic risk factor for schizophrenia.
|
28104410 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism, -141C insertion/deletion (Ins/Del) (rs1799732), in the promoter region of the dopamine D2 receptor gene has been linked to schizophrenia; however, the data are inconclusive.
|
26346037 |
2016 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 7 gene polymorphisms from DRD2 (rs1800497, rs1079597, rs1800498, rs1801028) and 5-HT2 A (rs6313, rs6311, rs6305) were genotyped for their association with schizophrenia.
|
30389402 |
2019 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After Bonferroni correction, there was no association found between DRD2 gene promoter region with schizophrenia risk in the northern Chinese Han population.
|
30657260 |
2019 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although less intensively studied than substance use disorders, the DRD2 gene has been implicated in Tourette's syndrome (TS), post-traumatic stress disorder (PTSD) and certain symptoms associated with affective disorders and schizophrenia.
|
11256581 |
2000 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although more family-based studies are needed to confirm this relation, our results provide strong evidence that DRD2 influences susceptibility to schizophrenia.
|
14593428 |
2003 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the clinical efficacy of dopamine D2 receptor antagonists against positive symptoms of schizophrenia supports the dopamine hypothesis of the disease, the resistance of negative and cognitive symptoms to these drugs implicates other systems in its pathophysiology.
|
31291870 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the Van Rossum hypothesis of dopamine receptor overactivity in schizophrenia is supported by the antagonism of, or reduced dopamine neurotransmission at, dopamine D2 receptors by antipsychotics, it has been claimed that the antipsychotic (-)-OSU6162 has a very low affinity for the dopamine D2 receptor, and has only autoreceptor dopamine D2 receptor-stimulating action, and, therefore, in order to explain its clinical action, the drug must stimulate dopamine D2 receptors that are defective or underactive in schizophrenia.
|
17157291 |
2007 |